Keytruda (pembrolizumab) - Merck (MSD)
Keytruda: Data from P3 KEYNOTE-412 trial (NCT03040999) for locally advanced HNSCC in 2023 (Merck (MSD)) - Jun 21, 2019 - Investor Day: Data from P3 KEYNOTE-756 trial (NCT03725059) for ER+/HER2- breast cancer in 2026 or later 
P3 data
https://investors.merck.com/events-and-presentations/default.aspx
 
Jun 21, 2019
 
 
0b1becab-a688-4b10-9e2b-380507a8f46f.jpg